Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of CYP2D6 genotype and response to tetrabenazine.

Movement disorders : official journal of the Movement Disorder Society - 1 Feb 2013

Mehanna Raja, Hunter Christine, Davidson Anthony, Jimenez-Shahed Joohi, Jankovic Joseph

Abstract excerpt

Tetrabenazine is effective in the treatment of the chorea associated with Huntington disease and other hyperkinetic movement disorders. Following oral administration, tetrabenazine is hepatically transformed into 2 active metabolites that are CYP2D6 substrates. There are 4 CYP2D6 genotypes: poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultrarapid metabolizers. CYP2D6 genotyping was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Huntington Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperkinesis

Share to Movement Disorders

Share to Myoclonus

Share to Pharmacogenetics

Share to Tourette Syndrome

Share to Treatment Outcome

Source

Identifiers

PMID: 23280482
DOI: 10.1002/mds.25278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of CYP2D6 genotype and response to tetrabenazine.PMID 23280482Read ↗

Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.Semantic proximity Read ↗

Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.Semantic proximity Read ↗

Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report.Semantic proximity Read ↗

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.Semantic proximity Read ↗

Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.Semantic proximity Read ↗

Pharmacogenetics of classical and new antipsychotic drugs.Semantic proximity Read ↗

CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.Semantic proximity Read ↗

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?Semantic proximity Read ↗

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.Semantic proximity Read ↗

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.Semantic proximity Read ↗

Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.Semantic proximity Read ↗

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.